Analyst Price Targets — MRK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 9:04 pm | Trung Huynh | RBC Capital | $142.00 | $123.93 | StreetInsider | RBC Capital Starts Merck (MRK) at Outperform |
| February 13, 2026 1:30 pm | James Shin | Deutsche Bank | $150.00 | $121.53 | TheFly | Merck upgraded to Buy from Hold at Deutsche Bank |
| February 4, 2026 12:48 pm | Asad Haider | Goldman Sachs | $133.00 | $115.86 | TheFly | Merck price target raised to $133 from $120 at Goldman Sachs |
| February 4, 2026 12:46 pm | — | BMO Capital | $135.00 | $115.86 | TheFly | Merck price target raised to $135 from $130 at BMO Capital |
| February 4, 2026 11:52 am | — | Bernstein | $100.00 | $115.86 | TheFly | Merck price target raised to $100 from $95 at Bernstein |
| February 3, 2026 6:18 pm | — | Scotiabank | $136.00 | $116.37 | TheFly | Merck price target raised to $136 from $120 at Scotiabank |
| January 27, 2026 12:22 pm | — | Cantor Fitzgerald | $116.00 | $107.40 | TheFly | Merck price target raised to $116 from $83 at Cantor Fitzgerald |
| January 8, 2026 11:41 am | — | Wolfe Research | $135.00 | $108.59 | TheFly | Merck upgraded to Outperform from Peer Perform at Wolfe Research |
| January 7, 2026 1:15 pm | — | UBS | $130.00 | $110.96 | TheFly | Merck price target raised to $130 from $105 at UBS |
| December 18, 2025 9:29 am | — | BMO Capital | $130.00 | $99.21 | TheFly | Merck upgraded to Outperform from Market Perform at BMO Capital |
Latest News for MRK
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
ImmunityBio's recently approved cancer drug has plenty of momentum. However, valuation concerns and clinical and regulatory uncertainty make the stock risky.
Most dividend investors seek solid passive income streams from quality dividend stocks.
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a…
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.